Completion of Phase 2 Enrollment for VK2735 Obesity Therapy

Viking Therapeutics announced the successful completion of patient enrollment in the Phase 2 VENTURE trial studying VK2735, an oral formulation designed for obesity treatment. VK2735 is a selective thyroid hormone receptor beta agonist that aims to increase metabolism and reduce body weight with minimized cardiovascular side effects compared to traditional thyroid hormone therapies. The double-blind, placebo-controlled study will evaluate efficacy, safety, and tolerability over 12 weeks in patients with moderate to severe obesity.

Completion of enrollment is a critical step toward generating robust data supporting VK2735’s potential as a novel oral treatment across diverse patient populations. Viking plans to report top-line results by late 2025.

Bluejay Therapeutics Advances Stem Cell-Based Neurological Research

Bluejay Therapeutics updated on its preclinical and early clinical programs targeting neurodegenerative diseases, including Parkinson’s and Huntington’s diseases. The company is focusing on gene therapies and cell transplantation techniques designed to promote neurological repair and restore motor function. Recent progress includes expansion of patient recruitment and refinement of therapeutic delivery methods aimed at improving safety and efficacy profiles.

These efforts are part of a broader push to develop transformative treatments addressing currently unmet needs in neurodegenerative conditions, which affect millions worldwide.

Innovations Driving Therapeutic Development

Both companies exemplify innovative pathways in drug development—Viking advancing selective receptor modulation for metabolic diseases, and Bluejay utilizing cutting-edge regenerative biology approaches for neurological disorders. These strategies reflect a growing emphasis on precision medicine and alternative delivery technologies.

Outlook: Accelerating Clinical Milestones and Patient Impact

With Phase 2 data expected soon, Viking Therapeutics is poised to pivot toward larger-scale studies and potential commercial partnerships. Bluejay’s clinical pipeline expansion signals a growing commitment to regenerative therapies for neurodegenerative diseases. Together, these developments reinforce confidence in the biopharma sector’s capacity to deliver meaningful advances in chronic disease management.